JP2013177454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013177454A5 JP2013177454A5 JP2013124891A JP2013124891A JP2013177454A5 JP 2013177454 A5 JP2013177454 A5 JP 2013177454A5 JP 2013124891 A JP2013124891 A JP 2013124891A JP 2013124891 A JP2013124891 A JP 2013124891A JP 2013177454 A5 JP2013177454 A5 JP 2013177454A5
- Authority
- JP
- Japan
- Prior art keywords
- oil
- formulation
- alpha
- tocopherol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 15
- 239000004359 castor oil Substances 0.000 claims description 7
- 235000019438 castor oil Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- UDSFVOAUHKGBEK-CNQKSJKFSA-N [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims description 5
- 229960000746 testosterone undecanoate Drugs 0.000 claims description 3
- -1 fatty acid esters Chemical class 0.000 claims 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical group OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 4
- 229960000984 tocofersolan Drugs 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims 2
- 229960003604 Testosterone Drugs 0.000 claims 2
- 229940087168 alpha Tocopherol Drugs 0.000 claims 2
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 2
- 235000004835 α-tocopherol Nutrition 0.000 claims 2
- 239000002076 α-tocopherol Substances 0.000 claims 2
- 235000019489 Almond oil Nutrition 0.000 claims 1
- 235000019482 Palm oil Nutrition 0.000 claims 1
- 229940068065 Phytosterols Drugs 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 229960001295 Tocopherol Drugs 0.000 claims 1
- 239000008168 almond oil Substances 0.000 claims 1
- 239000003240 coconut oil Substances 0.000 claims 1
- 235000019864 coconut oil Nutrition 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000002540 palm oil Substances 0.000 claims 1
- 235000019477 peppermint oil Nutrition 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 150000003515 testosterones Chemical class 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229930003799 tocopherols Natural products 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 229940100802 Aveed Drugs 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N Cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 Cinnarizine Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N Clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229960002336 Estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N Estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 Fenofibrate Drugs 0.000 description 1
- 229960002200 Flunitrazepam Drugs 0.000 description 1
- 229960003528 Flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N Flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- FJIKWRGCXUCUIG-UHFFFAOYSA-N Lormetazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 229960001454 Nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N Nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- GKZARTFJSANTLY-UHFFFAOYSA-N Sumatriptan Chemical compound [CH]1C(CS(=O)(=O)NC)=CC=C2N=CC(CCN(C)C)=C21 GKZARTFJSANTLY-UHFFFAOYSA-N 0.000 description 1
- 229960003708 Sumatriptan Drugs 0.000 description 1
- 229960003188 Temazepam Drugs 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N Triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000000147 hypnotic Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
Description
米国で臨床開発段階にあるウンデカン酸テストステロンの1つの剤形は、商業的にAveed(登録商標)(米国外ではNebido(登録商標))として知られており、ヒマシ油中に250mgのウンデカン酸テストステロンを含有する。2、3又は4mLの製剤(500、750、1000mgTU)を筋内注射により投与すると、注射部位の刺激、肺の油塞栓症及び/又は注射アナフィラキシー反応を示した。海外では、この製剤(4mLで1000mgTU;他の成分:ヒマシ油及びベンジルベンゾエート)は様々な国で使用が認められており、推奨の投与計画は、初回投与で1000mg、6週間後直ちに任意選択による2回目の1000mg、その後、引き続いて毎10〜14週に1000mgとするものである。
さらにまた、本発明の製剤の治療薬は、コレステロール低下薬及びトリグリセリド低下薬:フェノフィブレート、ロバスタチン、シンバスタチン、プラバスタチン、フルバスタチン、アトルバスタチン、又はセリバスタチン;抗不安薬、鎮静剤、及び催眠薬:ジアゼパム、ニトラゼパム、フルラゼパム、エスタゾラム、フルニトラゼパム、トリアゾラム、アルプラゾラム、ミダゾラム、テマゼパム、ロルメタゼパム、ブロチゾラム、クロバザム、クロナゼパム、ロラゼパム、オキサゼパム、ブスピロンなど;偏頭痛解消薬:スマトリプタン、エルゴタミン及び誘導体など;乗り物酔い防止薬:シナリジン、抗ヒスタミンなど:鎮吐剤:オンダンセトロン、トロピセトロン、グラニセトロン、メトクロプラミドなど;ジスルフィラム;及びビタミンKから選択してもよい。
Claims (15)
- 1種以上の治療薬の医薬的投与のための、事前濃縮物である、エマルション又はマイクロエマルション製剤であって、
a)テストステロン、テストステロンエステル、及びこれらの組み合わせからなる群から選択される、少なくとも1種の親油性で難水溶性の治療薬;
b)界面活性剤の組み合わせ;及び
c)フィトステロール及び/又はフィトステロール脂肪酸エステル
を含み、
前記製剤が自己乳化性である製剤。 - 前記テストステロンエステルが、ウンデカン酸テストステロンである、請求項1に記載の製剤。
- 前記少なくとも1種の治療薬が、製剤の0.1〜40重量%である、請求項1に記載の製剤。
- 前記界面活性剤の組み合わせが、ポリオキシエチレン−ソルビタン−脂肪酸エステル、ポリオキシエチレンヒマシ油、ポリオキシエチレン水素化ヒマシ油及びこれらの組み合わせからなる群から選択される界面活性剤を含む、請求項1に記載の製剤。
- 前記界面活性剤の組み合わせが、ポリオキシエチレンヒマシ油又はポリオキシエチレン水素化ヒマシ油を含む、請求項1に記載の製剤。
- 前記界面活性剤の組み合わせが、独立して1〜50重量%である、請求項1に記載の製剤。
- 前記フィトステロール及び/又はフィトステロール脂肪酸エステルが、製剤の2〜45重量%である、請求項1に記載の製剤。
- さらに可溶化剤を含む、請求項1に記載の製剤。
- 前記可溶化剤が、製剤の0.01〜90重量%である、請求項8に記載の製剤。
- 前記可溶化剤が、dl−アルファ−トコフェロール、アルファ−トコフェロールパルミテート、アルファ−トコフェロールアセテート、アルファ−トコフェリルポリエチレングリコールスクシネート(ビタミンE TPGS)、トコフェロール、トリグリセリド、ジグリセリド、モノグリセリド、グリセリド混合物、中鎖長の脂肪酸エステル及び長鎖長の脂肪酸エステルからなる群から選択される、請求項8に記載の製剤。
- 前記dl−アルファトコフェロール、アルファ−トコフェロールパルミテート、アルファ−トコフェロールアセテート、又はアルファ−トコフェリルポリエチレングリコールスクシネート(ビタミンE TPGS)が、製剤の0〜2重量%である、請求項10に記載の製剤。
- さらに脂質を含む、請求項1に記載の製剤。
- 前記脂質が、製剤の30重量%以下である、請求項12に記載の製剤。
- 前記脂質が、大豆油、ベニバナ油、コーン油、オリーブ油、ヒマシ油、綿実油、ヒマワリ油、ココナッツ油、パーム油、菜種油、ゴマ油、アーモンド油及びペパーミント油からなる群から選択される植物油を含む、請求項12に記載の製剤。
- さらに1種以上の追加の疎水性治療薬を含む、請求項1に記載の製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29176909P | 2009-12-31 | 2009-12-31 | |
US61/291,769 | 2009-12-31 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012547323A Division JP5847730B2 (ja) | 2009-12-31 | 2010-12-31 | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013177454A JP2013177454A (ja) | 2013-09-09 |
JP2013177454A5 true JP2013177454A5 (ja) | 2015-04-30 |
JP5836322B2 JP5836322B2 (ja) | 2015-12-24 |
Family
ID=44188274
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012547323A Active JP5847730B2 (ja) | 2009-12-31 | 2010-12-31 | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
JP2013124891A Active JP5836322B2 (ja) | 2009-12-31 | 2013-06-13 | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012547323A Active JP5847730B2 (ja) | 2009-12-31 | 2010-12-31 | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 |
Country Status (8)
Country | Link |
---|---|
US (5) | US20110160168A1 (ja) |
EP (2) | EP2519230B1 (ja) |
JP (2) | JP5847730B2 (ja) |
CA (1) | CA2822435C (ja) |
ES (1) | ES2710149T3 (ja) |
PL (1) | PL2519230T3 (ja) |
PT (1) | PT2519230T (ja) |
WO (1) | WO2011082384A2 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
RU2623206C2 (ru) | 2005-04-15 | 2017-06-22 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
PT2519230T (pt) | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
JP6368645B2 (ja) | 2011-09-29 | 2018-08-01 | ピーエルエックス オプコ インコーポレーテッド | 胃腸管に沿った医薬の標的化放出のためのpH依存性担体、それによる組成物、ならびにこれらの製造および使用 |
WO2014096139A1 (en) * | 2012-12-20 | 2014-06-26 | Solural Pharma ApS | Solid oral dosage form of testosterone derivative |
WO2014143127A1 (en) | 2013-03-15 | 2014-09-18 | Differential Drug Development Associates Llc | Emulsion formulations |
US10201549B2 (en) * | 2013-06-14 | 2019-02-12 | Professional Compounding Centers Of America (Pcca) | Testosterone combined with anastrozole injection solutions |
KR101786532B1 (ko) * | 2013-12-11 | 2017-10-18 | 헬스-에버 바이오테크 컴퍼니 리미티드 | 카로테노이드의 약제 조성물 |
MX2016016612A (es) * | 2014-06-17 | 2017-03-20 | Merck Sharp & Dohme | Formulaciones estables de undecanoato de testosterona. |
EP3157508B1 (en) * | 2014-06-19 | 2020-12-09 | Solural Pharma Aps | Solid oral dosage form of lipophilic compounds |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
RU2017111503A (ru) * | 2014-08-29 | 2018-10-05 | Липосин Инк. | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
KR101679380B1 (ko) * | 2015-09-10 | 2016-11-25 | 주식회사 유유제약 | 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형 |
KR101634382B1 (ko) * | 2015-10-20 | 2016-06-28 | 미래제약 주식회사 | 타다라필 경구용 액제 |
WO2018075665A1 (en) * | 2016-10-20 | 2018-04-26 | Axim Biotechnologies, Inc. | Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists |
WO2018098501A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
CA3064464A1 (en) * | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
CN109419771B (zh) * | 2017-08-28 | 2022-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 十一酸睾酮缓释药物组合物、其制备方法及用途 |
CA3177229A1 (en) * | 2017-08-30 | 2019-03-07 | Antares Pharma, Inc. | Testosterone ester triglyceride formulations |
CN107875034B (zh) * | 2017-10-11 | 2021-01-26 | 广东药科大学 | 一种复合抗氧化自微乳及其制备方法和应用 |
WO2019087696A1 (ja) * | 2017-11-01 | 2019-05-09 | 富士フイルム株式会社 | 経口医薬組成物 |
CN111315372A (zh) * | 2017-11-06 | 2020-06-19 | 凯特贝希制药公司 | 用于治疗肌营养不良症的艾得奈生给药方案 |
MX2019004191A (es) * | 2017-11-07 | 2020-02-12 | Poviva Tea Llc | Composiciones de alimentos y bebidas que comprenden inhibidores de pde5. |
GR1009542B (el) | 2018-04-25 | 2019-06-07 | Φαρματεν Α.Β.Ε.Ε. | Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων |
KR102051808B1 (ko) | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
JP2022523704A (ja) * | 2019-01-25 | 2022-04-26 | シェンチェン・ファーマシン・カンパニー・リミテッド | 医薬組成物 |
US20220265678A1 (en) * | 2019-10-30 | 2022-08-25 | Marius Pharmaceuticals Llc | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
JP2023518822A (ja) | 2020-03-26 | 2023-05-08 | ピーエルエックス オプコ インコーポレイテッド | pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法 |
MX2023013734A (es) * | 2021-05-19 | 2024-02-07 | Marius Pharmaceuticals Llc | Terapia oral con undecanoato de testosterona preferida para lograr el tratamiento de reemplazo de testosterona. |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
EP0265080B1 (en) | 1986-09-25 | 1991-11-27 | Nec Corporation | Device for detecting bit phase difference |
US5229370A (en) * | 1988-08-15 | 1993-07-20 | Ammeraal Robert N | Water soluble branched beta cyclodextrin steroid complex |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
DE69842121D1 (de) * | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
DE69939258D1 (de) | 1998-05-15 | 2008-09-18 | Nasa Johnson Space Ct | Mikrokapseln mit extern ausgelöster öffnung |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
DE19825591A1 (de) * | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
US6977083B1 (en) * | 1998-10-02 | 2005-12-20 | Jenapharm Gmbh & Co. Kg | Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6652880B1 (en) * | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
MXPA03001147A (es) * | 2000-08-23 | 2003-10-06 | Akzo Nobel Nv | Nueva formulacion de ester de testosterona para uso humano. |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
WO2002055020A2 (en) * | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
US20030203043A1 (en) * | 2002-04-25 | 2003-10-30 | A. Braswell | Composition and method for increasing testosterone levels |
US20030212046A1 (en) | 2002-05-07 | 2003-11-13 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
US20050287203A1 (en) | 2002-05-08 | 2005-12-29 | Nijs De H | Formulation comprising testosteron undecanoate and castor oil |
US6742488B2 (en) | 2002-07-18 | 2004-06-01 | Kohler Co. | Component for governing air flow in and around cylinder head port |
US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
US20080305177A1 (en) * | 2002-11-14 | 2008-12-11 | Alvin Kershman | Method of administering testosterone |
WO2004043434A1 (en) * | 2002-11-14 | 2004-05-27 | Shear/Kershman Laboratories, Inc. | Oral testosterone delivery system with improved sustained release |
US6742448B1 (en) | 2002-12-09 | 2004-06-01 | J. U. Manufacturing Co., Inc. | Baler with doors and platen positions interlocks |
US20040115226A1 (en) * | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
US20050100608A1 (en) * | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
EP1684769A2 (en) * | 2003-11-20 | 2006-08-02 | Zomanex, Llc | Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
US20080249076A1 (en) * | 2003-12-03 | 2008-10-09 | Lifecycle Pharma A/S | Pharmaceutical Compositions Comprising Danazol |
IL159729A0 (en) * | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
US7138389B2 (en) * | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
BRPI0513461A2 (pt) * | 2004-08-10 | 2011-05-10 | Enzymotec Ltd | mÉtodos de tratamento requerendo fito-ingredientes |
WO2006084312A1 (en) * | 2005-02-09 | 2006-08-17 | Acrux Dds Pty Ltd | Method of promoting hair growth |
KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
US8492369B2 (en) * | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
RU2623206C2 (ru) * | 2005-04-15 | 2017-06-22 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
US20080200533A1 (en) * | 2005-07-04 | 2008-08-21 | Ramu Krishnan | Drug or Pharmaceutical Compounds and a Preparation Thereof |
US7588274B2 (en) | 2005-07-06 | 2009-09-15 | Landon Worthington | Building block lifting and carrying tool |
JP2009532342A (ja) * | 2006-03-31 | 2009-09-10 | パナセア バイオテック リミテッド | 体毛疾患用の新規な組成物およびその調製方法 |
WO2007124598A2 (en) * | 2006-05-01 | 2007-11-08 | Forbes Medi-Tech Inc. | Softgel capsules with phytosterols and/or phytostanols and optionlly omega polyunstaurated fatty acids |
US20080124387A1 (en) * | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
US20080261937A1 (en) * | 2007-03-23 | 2008-10-23 | Dudley Robert E | Pharmaceutical compositions and method for treating pediatric hypogonadism |
US20090077961A1 (en) | 2007-09-24 | 2009-03-26 | Baker David M | Heat Concentrator Piston and Chamber |
EP2140861A1 (en) | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2229936B1 (en) | 2009-03-09 | 2015-05-06 | PharmaSol GmbH | Nanonized testosterone formulations for improved bioavailability |
US20110263552A1 (en) * | 2009-12-31 | 2011-10-27 | Sov Therapeutics | Modulation of side effect profile of 5-alpha reductase inhibitor therapy |
PT2519230T (pt) | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
US20130303495A1 (en) | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
US8512794B2 (en) * | 2010-05-20 | 2013-08-20 | Perlman Consulting, Llc | Oleate ester phytosterol compositions |
US9375437B2 (en) * | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US20120135074A1 (en) * | 2010-11-30 | 2012-05-31 | Chandrashekar Giliyar | High-Strength Testosterone Undecanoate Compositions |
US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2014143127A1 (en) | 2013-03-15 | 2014-09-18 | Differential Drug Development Associates Llc | Emulsion formulations |
WO2016049382A1 (en) | 2014-09-24 | 2016-03-31 | Lipocine Inc. | Compositions and their use in oral dosing regimens |
US20200197413A1 (en) | 2018-12-20 | 2020-06-25 | Clarus Therapeutics, Inc. | Methods of treating testosterone deficiency |
US11564933B2 (en) | 2019-04-12 | 2023-01-31 | Tolmar, Inc. | Methods of treating testosterone deficiency |
US20220265678A1 (en) | 2019-10-30 | 2022-08-25 | Marius Pharmaceuticals Llc | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
-
2010
- 2010-12-31 PT PT10841783T patent/PT2519230T/pt unknown
- 2010-12-31 JP JP2012547323A patent/JP5847730B2/ja active Active
- 2010-12-31 WO PCT/US2010/062649 patent/WO2011082384A2/en active Application Filing
- 2010-12-31 EP EP10841783.3A patent/EP2519230B1/en active Active
- 2010-12-31 ES ES10841783T patent/ES2710149T3/es active Active
- 2010-12-31 EP EP13170663.2A patent/EP2682111A1/en not_active Ceased
- 2010-12-31 PL PL10841783T patent/PL2519230T3/pl unknown
- 2010-12-31 CA CA2822435A patent/CA2822435C/en active Active
- 2010-12-31 US US12/983,216 patent/US20110160168A1/en not_active Abandoned
-
2013
- 2013-06-13 JP JP2013124891A patent/JP5836322B2/ja active Active
- 2013-07-05 US US13/936,036 patent/US10576089B2/en active Active
-
2018
- 2018-04-23 US US15/959,626 patent/US10576090B2/en active Active
-
2019
- 2019-11-26 US US16/696,159 patent/US11590146B2/en active Active
-
2023
- 2023-01-27 US US18/102,136 patent/US20240000798A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013177454A5 (ja) | ||
JP2013516433A5 (ja) | ||
JP7360521B2 (ja) | ω3脂肪酸の自己乳化組成物 | |
US10576090B2 (en) | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols | |
CA2760039C (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
US11617758B2 (en) | Emulsion formulations | |
JP2019214598A (ja) | 天然の併用ホルモン補充療法剤及び治療 | |
JP2020011958A (ja) | ω3脂肪酸の自己乳化組成物 | |
JP2015520235A5 (ja) | ||
CN107073127A (zh) | 亲脂性化合物的固体口服剂型 | |
AU2013282413B2 (en) | Racecadotril lipid compositions | |
ES2983643T3 (es) | Terapia oral con tridecanoato de testosterona | |
JP2016512828A5 (ja) | ||
JP2016512828A (ja) | ラセカドトリル脂質組成物 | |
CN100463669C (zh) | 复方蒿甲醚自乳化剂 | |
JP2018027949A (ja) | 医薬組成物 | |
ES2551125T3 (es) | Composición antifúngica | |
JP6484393B2 (ja) | デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤 | |
JP5795760B2 (ja) | ジヒドロアルテミシニンを含む舌下スプレー用製剤 | |
TW200840596A (en) | Microemulsion dosage forms of valsartan and methods of making the same | |
CA3044812A1 (en) | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione | |
CN111356450A (zh) | Pde5抑制剂的液体填充制剂 | |
JP2022088622A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
Garg et al. | Application of self-emulsifying delivery systems for effective delivery of nutraceuticals | |
US20230075007A1 (en) | Pharmaceutical formulations of cannabidiol |